Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Intrathecal Injection of Sacituzumab Tirumotecan (SKB264) in the Treatment of Leptomeningeal Metastasis From EGFR-TKI-Resistant Non-Small Cell Lung Cancer

NCT07702305 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07702305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07702305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Intrathecal Injection of Sacituzumab Tirumotecan (SKB264) in the Treatment of Leptomeningeal Metastasis From EGFR-TKI-Resistant Non-Small Cell Lung Cancer
Lead sponsor
Henan Cancer Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 23, 2026
Completion date
December 31, 2027
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr-tki-resistant non-small cell lung cancer with leptomeningeal metastasis